These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

460 related items for PubMed ID: 37309038

  • 21. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
    Beusekamp JC, Tromp J, Cleland JGF, Givertz MM, Metra M, O'Connor CM, Teerlink JR, Ponikowski P, Ouwerkerk W, van Veldhuisen DJ, Voors AA, van der Meer P.
    JACC Heart Fail; 2019 Nov; 7(11):970-979. PubMed ID: 31606364
    [Abstract] [Full Text] [Related]

  • 22. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
    Mavrakanas TA, Gariani K, Martin PY.
    Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care.
    Bidulka P, Fu EL, Leyrat C, Kalogirou F, McAllister KSL, Kingdon EJ, Mansfield KE, Iwagami M, Smeeth L, Clase CM, Bhaskaran K, van Diepen M, Carrero JJ, Nitsch D, Tomlinson LA.
    BMC Med; 2020 Jul 29; 18(1):195. PubMed ID: 32723383
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Treatment of diabetic kidney disease. A network meta-analysis.
    Büttner F, Barbosa CV, Lang H, Tian Z, Melk A, Schmidt BMW.
    PLoS One; 2023 Jul 29; 18(11):e0293183. PubMed ID: 37917640
    [Abstract] [Full Text] [Related]

  • 27. Combined use of renin-angiotensin-aldosterone system-acting agents: a cross-sectional study.
    Farcas A, Leucuta D, Bucsa C, Mogosan C, Dumitrascu D.
    Int J Clin Pharm; 2016 Dec 29; 38(6):1390-1397. PubMed ID: 27677980
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Acute Kidney Disease after an Episode of AKI: A Multicenter Prospective Cohort Study.
    Hines A, Li X, Ortiz-Soriano V, Saleh S, Litteral J, Ruiz-Conejo M, Wald R, Silver SA, Neyra JA.
    Am J Nephrol; 2020 Dec 29; 51(4):266-275. PubMed ID: 32088714
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C, Pöss J, Böhm M.
    Drugs; 2010 Jul 09; 70(10):1215-30. PubMed ID: 20568830
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use prior to major elective surgery and the risk of acute dialysis.
    Shah M, Jain AK, Brunelli SM, Coca SG, Devereaux PJ, James MT, Luo J, Molnar AO, Mrkobrada M, Pannu N, Parikh CR, Paterson M, Shariff S, Wald R, Walsh M, Whitlock R, Wijeysundera DN, Garg AX.
    BMC Nephrol; 2014 Apr 02; 15():53. PubMed ID: 24694072
    [Abstract] [Full Text] [Related]

  • 34. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF.
    Cochrane Database Syst Rev; 2009 Jul 08; (3):CD007004. PubMed ID: 19588415
    [Abstract] [Full Text] [Related]

  • 35. A Real-World Analysis of Post-Marketing Surveillance Data Assessing the Incidence of Hyperkalemia or Acute Kidney Injury in Patients on Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin-Receptor Blockers.
    Wang Y, Ren Q, Luo H, Chen G, Zhao B, Li X.
    Rev Cardiovasc Med; 2023 Apr 08; 24(4):107. PubMed ID: 39076277
    [Abstract] [Full Text] [Related]

  • 36. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR, Rolfe M.
    Clin J Am Soc Nephrol; 2010 Mar 08; 5(3):531-48. PubMed ID: 20150448
    [Abstract] [Full Text] [Related]

  • 37. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
    Lee J, Lee S.
    Pharmacotherapy; 2018 Nov 08; 38(11):1095-1105. PubMed ID: 30225928
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. "Renalism" with Renin Angiotensin Aldosterone System Inhibitor Use in Patients Enrolled in Trials for Heart Failure with Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Systematic Review.
    Sudani HA, Shah S, Lo KB, Essa H, Wattoo A, Angelim L, Brousas S, Whybrow-Huppatz I, Vellanki S, Sankaranarayanan R, Rangaswami J.
    Curr Vasc Pharmacol; 2023 Nov 08; 21(2):106-110. PubMed ID: 36918781
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.